Article
Anti-cancer efficacy of SREBP inhibitor, alone or in combination with docetaxel, in prostate cancer harboring p53 mutations.
Oncotarget - 1 Dec 2015
Li Xiangyan, Wu Jason Boyang, Chung Leland W K, Huang Wen-Chin
Abstract excerpt
Mutant p53 proteins (mutant p53s) have oncogenic gain-of-function properties correlated with tumor grade, castration resistance, and prostate cancer (PCa) tumor recurrence. Docetaxel is a standard first-line treatment for metastatic castration-resistant PCa (mCRPC) after the failure of hormone therapy. However, most mCRPC patients who receive docetaxel experience only transient benefits and rapidly develop...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.